KeyMed Biosciences Inc
HKEX:2162
US |
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
|
US |
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
|
US |
Bank of America Corp
NYSE:BAC
|
Banking
|
|
US |
Mastercard Inc
NYSE:MA
|
Technology
|
|
US |
Abbvie Inc
NYSE:ABBV
|
Biotechnology
|
|
US |
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
|
US |
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
|
US |
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
|
US |
Visa Inc
NYSE:V
|
Technology
|
|
CN |
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
|
US |
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
|
US |
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
|
US |
Coca-Cola Co
NYSE:KO
|
Beverages
|
|
US |
Realty Income Corp
NYSE:O
|
Real Estate
|
|
US |
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
|
US |
Walt Disney Co
NYSE:DIS
|
Media
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
This note will be permanently deleted.
KeyMed Biosciences Inc
Cash from Operating Activities
KeyMed Biosciences Inc
Cash from Operating Activities Peer Comparison
Competitive Cash from Operating Activities Analysis
Latest Figures & CAGR of Competitors
Company | Cash from Operating Activities | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
K
|
KeyMed Biosciences Inc
HKEX:2162
|
Cash from Operating Activities
-ÂĄ303.6m
|
CAGR 3-Years
-37%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
Beigene Ltd
HKEX:6160
|
Cash from Operating Activities
-ÂĄ7.8B
|
CAGR 3-Years
-15%
|
CAGR 5-Years
-13%
|
CAGR 10-Years
N/A
|
|
Innovent Biologics Inc
HKEX:1801
|
Cash from Operating Activities
ÂĄ147.8m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Beijing Wantai Biological Pharmacy Enterprise Co Ltd
SSE:603392
|
Cash from Operating Activities
ÂĄ1.5B
|
CAGR 3-Years
49%
|
CAGR 5-Years
49%
|
CAGR 10-Years
N/A
|
|
Chongqing Zhifei Biological Products Co Ltd
SZSE:300122
|
Cash from Operating Activities
ÂĄ5.8B
|
CAGR 3-Years
14%
|
CAGR 5-Years
134%
|
CAGR 10-Years
43%
|
|
Imeik Technology Development Co Ltd
SZSE:300896
|
Cash from Operating Activities
ÂĄ1.2B
|
CAGR 3-Years
57%
|
CAGR 5-Years
70%
|
CAGR 10-Years
N/A
|
See Also
What is KeyMed Biosciences Inc's Cash from Operating Activities?
Cash from Operating Activities
-303.6m
CNY
Based on the financial report for Dec 31, 2023, KeyMed Biosciences Inc's Cash from Operating Activities amounts to -303.6m CNY.
What is KeyMed Biosciences Inc's Cash from Operating Activities growth rate?
Cash from Operating Activities CAGR 3Y
-37%
Over the last year, the Cash from Operating Activities growth was 24%. The average annual Cash from Operating Activities growth rates for KeyMed Biosciences Inc have been -37% over the past three years .